High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Jo-Ann See, Kurt Gebauer, Jason K. Wu, Shobhan Manoharan, Nabil Kerrouche, John Sullivan

ABSTRACT

INTRODUCTION: Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK. METHODS: A multicenter, prospective, observational study was conducted in Australia in patients receiving a single treatment of MAL DL-PDT for mild to moderate AK. Efficacy was assessed 3 months after treatment by investigator-assessed improvement and patient- and physician-completed satisfaction questionnaires. Adverse events were recorded throughout the study. RESULTS: Overall, 81 patients were enrolled of mean age 62.7 years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8 years). Most had multiple lesions (82.7% had >10 lesions) of predominantly grade I (75.3%). At 3 months after treatment, almost half the patients (46.8%) required no further treatment. The proportions of patients and physicians satisfied to very satisfied with the MAL DL-PDT treatment were 79.7% and 83.3%, respectively. After receiving the treatment, 74.1% of patients indicated via the questionnaire that they were not bothered at all by the pain. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%). CONCLUSIONS: In clinical practice in Australia, the use of MAL DL-PDT in treating multiple mild to moderate non-hyperkeratotic AK of the face and/or scalp results in high levels of patient and physician satisfaction reflecting the good efficacy and tolerability of this almost painless, convenient procedure. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02674048. FUNDING: Galderma R&D. More... »

PAGES

525-533

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13555-017-0199-9

DOI

http://dx.doi.org/10.1007/s13555-017-0199-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091596935

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28905294


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Central Sydney Dermatology, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "See", 
        "givenName": "Jo-Ann", 
        "id": "sg:person.01274442452.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274442452.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Fremantle Dermatology, Perth, WA, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gebauer", 
        "givenName": "Kurt", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Toowong Dermatology, Toowong, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Jason K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Westside Dermatology, Taringa, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manoharan", 
        "givenName": "Shobhan", 
        "id": "sg:person.01063411516.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063411516.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Galderma R&D, Sophia Antipolis, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kerrouche", 
        "givenName": "Nabil", 
        "id": "sg:person.0711702007.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711702007.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Kingsway Dermatology & Aesthetics, Miranda, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sullivan", 
        "givenName": "John", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10227-001-0041-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006099674", 
          "https://doi.org/10.1007/s10227-001-0041-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1523-1747.2000.00048.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010595039", 
          "https://doi.org/10.1046/j.1523-1747.2000.00048.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.2010.10089.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016411199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd004415.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019685506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021338180"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.1994.tb08544.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023783776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024718492"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2010.429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025283335", 
          "https://doi.org/10.1038/jid.2010.429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199310143291602", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030512417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13228", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034209415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.13138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037227871"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.2009.09562.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039602031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.2009.09562.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039602031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ajd.12295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041886313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13180", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044051574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ajd.12354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044728306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0015194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047487650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1894", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051508795", 
          "https://doi.org/10.1038/nrc1894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1894", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051508795", 
          "https://doi.org/10.1038/nrc1894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603792", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052923522", 
          "https://doi.org/10.1038/sj.bjc.6603792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1203475417702994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084826212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1203475417702994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084826212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/120347540200600301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090622235"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/120347540200600301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090622235"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "INTRODUCTION: Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK.\nMETHODS: A multicenter, prospective, observational study was conducted in Australia in patients receiving a single treatment of MAL DL-PDT for mild to moderate AK. Efficacy was assessed 3\u00a0months after treatment by investigator-assessed improvement and patient- and physician-completed satisfaction questionnaires. Adverse events were recorded throughout the study.\nRESULTS: Overall, 81 patients were enrolled of mean age 62.7\u00a0years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8\u00a0years). Most had multiple lesions (82.7% had >10 lesions) of predominantly grade I (75.3%). At 3\u00a0months after treatment, almost half the patients (46.8%) required no further treatment. The proportions of patients and physicians satisfied to very satisfied with the MAL DL-PDT treatment were 79.7% and 83.3%, respectively. After receiving the treatment, 74.1% of patients indicated via the questionnaire that they were not bothered at all by the pain. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%).\nCONCLUSIONS: In clinical practice in Australia, the use of MAL DL-PDT in treating multiple mild to moderate non-hyperkeratotic AK of the face and/or scalp results in high levels of patient and physician satisfaction reflecting the good efficacy and tolerability of this almost painless, convenient procedure.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02674048.\nFUNDING: Galderma R&D.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13555-017-0199-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1047318", 
        "issn": [
          "2193-8210", 
          "2190-9172"
        ], 
        "name": "Dermatology and Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia", 
    "pagination": "525-533", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3ea92c5d3b3f944c0468507dc78a87285269f9c880d945b033bbd4ad4f7328fb"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28905294"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101590450"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13555-017-0199-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091596935"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13555-017-0199-9", 
      "https://app.dimensions.ai/details/publication/pub.1091596935"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000525.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs13555-017-0199-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13555-017-0199-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13555-017-0199-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13555-017-0199-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13555-017-0199-9'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      21 PREDICATES      49 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13555-017-0199-9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na1f7c4de7a3943c396d2f72cb836f0bb
4 schema:citation sg:pub.10.1007/s10227-001-0041-x
5 sg:pub.10.1038/jid.2010.429
6 sg:pub.10.1038/nrc1894
7 sg:pub.10.1038/sj.bjc.6603792
8 sg:pub.10.1046/j.1523-1747.2000.00048.x
9 https://doi.org/10.1002/14651858.cd004415.pub2
10 https://doi.org/10.1056/nejm199310143291602
11 https://doi.org/10.1111/ajd.12295
12 https://doi.org/10.1111/ajd.12354
13 https://doi.org/10.1111/bjd.13138
14 https://doi.org/10.1111/j.1365-2133.1994.tb08544.x
15 https://doi.org/10.1111/j.1365-2133.2009.09562.x
16 https://doi.org/10.1111/j.1365-2133.2010.10089.x
17 https://doi.org/10.1111/jdv.13180
18 https://doi.org/10.1111/jdv.13228
19 https://doi.org/10.1111/jdv.13327
20 https://doi.org/10.1111/jdv.13449
21 https://doi.org/10.1177/120347540200600301
22 https://doi.org/10.1177/1203475417702994
23 https://doi.org/10.1371/journal.pone.0015194
24 schema:datePublished 2017-12
25 schema:datePublishedReg 2017-12-01
26 schema:description INTRODUCTION: Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK. METHODS: A multicenter, prospective, observational study was conducted in Australia in patients receiving a single treatment of MAL DL-PDT for mild to moderate AK. Efficacy was assessed 3 months after treatment by investigator-assessed improvement and patient- and physician-completed satisfaction questionnaires. Adverse events were recorded throughout the study. RESULTS: Overall, 81 patients were enrolled of mean age 62.7 years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8 years). Most had multiple lesions (82.7% had >10 lesions) of predominantly grade I (75.3%). At 3 months after treatment, almost half the patients (46.8%) required no further treatment. The proportions of patients and physicians satisfied to very satisfied with the MAL DL-PDT treatment were 79.7% and 83.3%, respectively. After receiving the treatment, 74.1% of patients indicated via the questionnaire that they were not bothered at all by the pain. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%). CONCLUSIONS: In clinical practice in Australia, the use of MAL DL-PDT in treating multiple mild to moderate non-hyperkeratotic AK of the face and/or scalp results in high levels of patient and physician satisfaction reflecting the good efficacy and tolerability of this almost painless, convenient procedure. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02674048. FUNDING: Galderma R&D.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N188dae51daf94c8cbde754fcfedcf845
31 N5a3485835cc44a3e891f32b4b3a79f8b
32 sg:journal.1047318
33 schema:name High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia
34 schema:pagination 525-533
35 schema:productId N7963bce4bf8549bb92cb420ec2aaa95d
36 N9928a4da42714cb99504fc541235820f
37 Na12d5d01f9bd4046a880a69a19735e42
38 Nea79e108ddae421a82a0136e360ca019
39 Nf6784446244c4f80b8cf02fe82065a08
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091596935
41 https://doi.org/10.1007/s13555-017-0199-9
42 schema:sdDatePublished 2019-04-10T22:35
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N6fd31f3d46db4ad3ab01e57ffa4f02f2
45 schema:url http://link.springer.com/10.1007%2Fs13555-017-0199-9
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N02d3d3d0d9ff4136b9b3a0309ac7dc9d schema:name Westside Dermatology, Taringa, QLD, Australia
50 rdf:type schema:Organization
51 N188dae51daf94c8cbde754fcfedcf845 schema:volumeNumber 7
52 rdf:type schema:PublicationVolume
53 N2b8bccba7da04ca894aab4771c690465 schema:affiliation Nebf08f58a27b477e87b2dc43af5002ec
54 schema:familyName Wu
55 schema:givenName Jason K.
56 rdf:type schema:Person
57 N2babdde8662b4944a8c43d30068d5fc1 schema:affiliation N5b60d4c2e5f44f63a01e931dcbb79c7c
58 schema:familyName Sullivan
59 schema:givenName John
60 rdf:type schema:Person
61 N5a3485835cc44a3e891f32b4b3a79f8b schema:issueNumber 4
62 rdf:type schema:PublicationIssue
63 N5b60d4c2e5f44f63a01e931dcbb79c7c schema:name Kingsway Dermatology & Aesthetics, Miranda, NSW, Australia
64 rdf:type schema:Organization
65 N6fd31f3d46db4ad3ab01e57ffa4f02f2 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N7963bce4bf8549bb92cb420ec2aaa95d schema:name dimensions_id
68 schema:value pub.1091596935
69 rdf:type schema:PropertyValue
70 N8fb782eee23e41aa90a3da1ad0df4c30 rdf:first N2babdde8662b4944a8c43d30068d5fc1
71 rdf:rest rdf:nil
72 N96ba04e016f4428d8a80409c079272f1 rdf:first sg:person.0711702007.10
73 rdf:rest N8fb782eee23e41aa90a3da1ad0df4c30
74 N9928a4da42714cb99504fc541235820f schema:name readcube_id
75 schema:value 3ea92c5d3b3f944c0468507dc78a87285269f9c880d945b033bbd4ad4f7328fb
76 rdf:type schema:PropertyValue
77 Na12d5d01f9bd4046a880a69a19735e42 schema:name nlm_unique_id
78 schema:value 101590450
79 rdf:type schema:PropertyValue
80 Na198828ec83e435cbca4d0dd82c9a200 schema:name Fremantle Dermatology, Perth, WA, Australia
81 rdf:type schema:Organization
82 Na1f7c4de7a3943c396d2f72cb836f0bb rdf:first sg:person.01274442452.80
83 rdf:rest Ne2e42455f63840d4af22476e6476fe5f
84 Nc4d766b48387404dbbe0716634b780e5 rdf:first N2b8bccba7da04ca894aab4771c690465
85 rdf:rest Nf935e3119fe44ec3b55bac2d6369aca5
86 Nd30e53d24c3f493f91ce538b91cd6a3a schema:name Central Sydney Dermatology, Sydney, NSW, Australia
87 rdf:type schema:Organization
88 Ne2e42455f63840d4af22476e6476fe5f rdf:first Nf453662108bb45c0a075cbffa6c9bb98
89 rdf:rest Nc4d766b48387404dbbe0716634b780e5
90 Nea79e108ddae421a82a0136e360ca019 schema:name pubmed_id
91 schema:value 28905294
92 rdf:type schema:PropertyValue
93 Neba7235ee94349f4bd4aaa024d28c25f schema:name Galderma R&D, Sophia Antipolis, France
94 rdf:type schema:Organization
95 Nebf08f58a27b477e87b2dc43af5002ec schema:name Toowong Dermatology, Toowong, QLD, Australia
96 rdf:type schema:Organization
97 Nf453662108bb45c0a075cbffa6c9bb98 schema:affiliation Na198828ec83e435cbca4d0dd82c9a200
98 schema:familyName Gebauer
99 schema:givenName Kurt
100 rdf:type schema:Person
101 Nf6784446244c4f80b8cf02fe82065a08 schema:name doi
102 schema:value 10.1007/s13555-017-0199-9
103 rdf:type schema:PropertyValue
104 Nf935e3119fe44ec3b55bac2d6369aca5 rdf:first sg:person.01063411516.98
105 rdf:rest N96ba04e016f4428d8a80409c079272f1
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
110 schema:name Clinical Sciences
111 rdf:type schema:DefinedTerm
112 sg:journal.1047318 schema:issn 2190-9172
113 2193-8210
114 schema:name Dermatology and Therapy
115 rdf:type schema:Periodical
116 sg:person.01063411516.98 schema:affiliation N02d3d3d0d9ff4136b9b3a0309ac7dc9d
117 schema:familyName Manoharan
118 schema:givenName Shobhan
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063411516.98
120 rdf:type schema:Person
121 sg:person.01274442452.80 schema:affiliation Nd30e53d24c3f493f91ce538b91cd6a3a
122 schema:familyName See
123 schema:givenName Jo-Ann
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274442452.80
125 rdf:type schema:Person
126 sg:person.0711702007.10 schema:affiliation Neba7235ee94349f4bd4aaa024d28c25f
127 schema:familyName Kerrouche
128 schema:givenName Nabil
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711702007.10
130 rdf:type schema:Person
131 sg:pub.10.1007/s10227-001-0041-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006099674
132 https://doi.org/10.1007/s10227-001-0041-x
133 rdf:type schema:CreativeWork
134 sg:pub.10.1038/jid.2010.429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025283335
135 https://doi.org/10.1038/jid.2010.429
136 rdf:type schema:CreativeWork
137 sg:pub.10.1038/nrc1894 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051508795
138 https://doi.org/10.1038/nrc1894
139 rdf:type schema:CreativeWork
140 sg:pub.10.1038/sj.bjc.6603792 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052923522
141 https://doi.org/10.1038/sj.bjc.6603792
142 rdf:type schema:CreativeWork
143 sg:pub.10.1046/j.1523-1747.2000.00048.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010595039
144 https://doi.org/10.1046/j.1523-1747.2000.00048.x
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1002/14651858.cd004415.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019685506
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1056/nejm199310143291602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030512417
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1111/ajd.12295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041886313
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1111/ajd.12354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044728306
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1111/bjd.13138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037227871
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1111/j.1365-2133.1994.tb08544.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023783776
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1111/j.1365-2133.2009.09562.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1039602031
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1111/j.1365-2133.2010.10089.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016411199
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1111/jdv.13180 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044051574
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1111/jdv.13228 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034209415
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1111/jdv.13327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024718492
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1111/jdv.13449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021338180
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1177/120347540200600301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090622235
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1177/1203475417702994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084826212
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1371/journal.pone.0015194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047487650
175 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...